Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (60)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rascol, O.
Right arrow Articles by Chollet, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rascol, O.
Right arrow Articles by Chollet, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 121, Issue 3 527-533, Copyright © 1998 by Oxford University Press

ARTICLES

Cortical motor overactivation in parkinsonian patients with L-dopa- induced peak-dose dyskinesia

O Rascol, U Sabatini, C Brefel, N Fabre, S Rai, JM Senard, P Celsis, G Viallard, JL Montastruc and F Chollet
INSERM U455, University Hospital of Toulouse, France.

We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects. Single photon emission tomography with i.v. 133Xe was used to measure the rCBF changes. The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non- dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas. These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
D. Rylander, A. Recchia, F. Mela, A. Dekundy, W. Danysz, and M. A. Cenci
Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 227 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
B. Thanvi, N. Lo, and T. Robinson
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Postgrad. Med. J., June 1, 2007; 83(980): 384 - 388.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Wagle-Shukla, M. J. Angel, C. Zadikoff, M. Enjati, C. Gunraj, A. E. Lang, and R. Chen
Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias
Neurology, February 27, 2007; 68(9): 704 - 705.
[Full Text] [PDF]

Home page
 NeurologyHome page
G. Koch, L. Brusa, C. Caltagirone, A. Peppe, M. Oliveri, P. Stanzione, and D. Centonze
rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease
Neurology, August 23, 2005; 65(4): 623 - 625.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
C. Buhmann, V. Glauche, H. J. Sturenburg, M. Oechsner, C. Weiller, and C. Buchel
Pharmacologically modulated fMRI---cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients
Brain, February 1, 2003; 126(2): 451 - 461.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
L. Escola, Th. Michelet, F. Macia, D. Guehl, B. Bioulac, and P. Burbaud
Disruption of information processing in the supplementary motor area of the MPTP-treated monkey: A clue to the pathophysiology of akinesia?
Brain, January 1, 2003; 126(1): 95 - 114.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. J. Canales, C. Capper-Loup, D. Hu, E. S. Choe, U. Upadhyay, and A. M. Graybiel
Shifts in striatal responsivity evoked by chronic stimulation of dopamine and glutamate systems
Brain, October 1, 2002; 125(10): 2353 - 2363.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Jankovic
Levodopa strengths and weaknesses
Neurology, February 1, 2002; 58(90001): S19 - 32.
[Abstract] [Full Text]

Home page
 BrainHome page
A. Berardelli, J. C. Rothwell, P. D. Thompson, and M. Hallett
Pathophysiology of bradykinesia in Parkinson's disease
Brain, November 1, 2001; 124(11): 2131 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Ulivelli, S. Rossi, P. Pasqualetti, P. M. Rossini, O. Ghiglieri, S. Passero, and N. Battistini
Time course of frontal somatosensory evoked potentials: Relation to L-dopa plasma levels and motor performance in PD
Neurology, October 22, 1999; 53(7): 1451 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. M. Gordon and R. Reilmann
Getting a grasp on research: does treatment taint testing of parkinsonian patients?
Brain, August 1, 1999; 122(8): 1597 - 1598.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.